TABLE 2

Risk reduction of progression of microvascular complications in the DCCT intensive treatment group comparing baseline C-peptide responders (≥0.2–0.5 nmol/l) vs. nonresponders (<0.2 nmol/l) with no adjustments, adjustment for baseline complication status, and adjustment for baseline status and HbA1c

UnadjustedAdjusted for baseline status*Adjusted for baseline status and HbA1c
Retinopathy
 ≥3-step progression58 (27–76)59 (29–77)50 (12–72)
 Sustained ≥3-step progression79 (9–95)79 (10–95)71 (−26 to 93)
Nephropathy (AER >40 mg/24 h)64 (−10 to 71)38 (−22 to 69)27 (−46 to 64)
  • Data are % risk reduction (95% CI).

  • *

    * Baseline status is presence or absence of retinopathy at baseline for analysis of retinopathy and the log(AER) at baseline for nephropathy.